Table 4

Stratified analysis for the association between sST2 and the primary endpoint (any cardiovascular event) and secondary endpoint (death or heart failure) according to women and men

HR*95%  CIP valueHR*95%  CIP value
Any cardiovascular event n=96 n=129
sST2 (univariable)1.801.30 to 2.49<0.0011.190.90 to 1.560.223
Adjusted for age1.721.22 to 2.440.0021.300.99 to 1.710.063
Adjusted for age and creatinine1.711.22 to 2.410.0021.280.97 to 1.690.080
Adjusted for age and NT-proBNP1.491.04 to 2.120.0291.160.89 to 1.510.274
Adjusted for age, NT-proBNP and creatinine1.481.04 to 2.110.0291.180.89 to 1.550.248
Adjusted for age, rhythm and systemic ventricular function1.671.20 to 2.330.0021.280.98 to 1.680.071
Adjusted for age, congenital diagnosis†, NYHA class and cardiac medication1.230.87 to 1.750.2401.300.99 to 1.700.056
Adjusted for full model‡1.260.89 to 1.790.1901.280.97 to 1.690.076
Adjusted for full model‡ and NT-proBNP1.170.81 to 1.690.4071.180.89 to 1.560.250
Death or heart failure n=40 n=29
sST2 (univariable)2.721.67 to 4.44<0.0011.470.81 to 2.650.201
Adjusted for age2.681.55 to 4.63<0.0011.831.03 to 3.230.039
Adjusted for age and creatinine2.681.55 to 4.62<0.0011.610.88 to 2.940.125
Adjusted for age and NT-proBNP2.031.12 to 3.690.0201.180.69 to 2.000.547
Adjusted for age, NT-proBNP and creatinine2.041.12 to 3.710.020– §
  • Analysis including all covariates (full model) was not performed for the secondary endpoint due to insufficient statistical power.

  • *HRs are expressed per twofold increase in sST2 level. P value of interaction between sex and sST2=0.047 (primary endpoint) and p=0.104 for secondary endpoint.

  • †Congenital diagnosis of arterial switch operation, aortic stenosis or aortic coarctation (0) versus tetralogy of Fallot, Rastelli, systemic right ventricle, univentricular heart or pulmonary arterial hypertension (1).

  • ‡Adjusted for age, creatinine, sinus rhythm, systemic ventricular function, congenital diagnosis, NYHA class 2–3 and cardiac medication.

  • §Insufficient statistical power to perform analysis.

  • NT-proBNP, N terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; sST2, soluble suppression of tumourigenicity-2.